Skip to main content
BYAH
NASDAQ Industrial Applications And Services

Amended Annual Report Reveals $24.36M Loss, Ineffective Internal Controls, and Significant Franchisee Decline

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$1.08
Mkt Cap
$3.478M
52W Low
$0.93
52W High
$2,074.5
Market data snapshot near publication time

summarizeSummary

Park Ha Biological Technology filed an amended annual report disclosing a $24.36 million net loss, ineffective internal controls, a significant drop in franchisees, and increased credit losses, alongside details of a recent capital raise and reverse stock split.


check_boxKey Events

  • Substantial Net Loss Reported

    The company reported a net loss of $24,364,753 for the fiscal year ended October 31, 2025, a significant reversal from a net income of $478,561 in the prior year. This loss was primarily driven by a $24,070,200 non-cash share-based compensation expense.

  • Internal Control Over Financial Reporting Deemed Ineffective

    Management concluded that the company's internal control over financial reporting was 'not effective' as of October 31, 2025, citing insufficient in-house personnel with adequate knowledge of U.S. GAAP and SEC reporting rules as a material weakness.

  • Significant Decline in Franchisees and Increased Credit Risk

    The number of franchisees decreased from 45 in 2024 to 22 in 2025, contributing to a 10% drop in franchise fee revenue. The allowance for expected credit losses on franchisee loans increased significantly to $232,876, with $0.9 million in loans due from terminated franchisees.

  • Recent Capital Raise and Reverse Stock Split

    The company completed a public offering on January 28, 2026, raising $2.45 million in gross proceeds by selling 21,875,000 units, each including a Class A Ordinary Share and a warrant. This was followed by a 1-for-50 reverse stock split effective February 20, 2026, to regain Nasdaq compliance.


auto_awesomeAnalysis

This amended annual report highlights severe financial and operational challenges for Park Ha Biological Technology. The company reported a substantial net loss, primarily driven by a large non-cash share-based compensation expense. Critically, management identified a material weakness in its internal controls over financial reporting, indicating significant deficiencies in financial oversight. The sharp decline in franchisees and a notable increase in uncollectible loans from them point to operational instability and heightened credit risk. While the company successfully raised capital and executed a reverse stock split, these actions appear reactive to underlying financial distress and Nasdaq compliance issues. Investors should be highly concerned about the company's financial health, internal control environment, and the sustainability of its franchise model.

At the time of this filing, BYAH was trading at $1.08 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.93 to $2,074.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BYAH - Latest Insights

BYAH
Apr 28, 2026, 7:00 PM EDT
Filing Type: 20-F/A
Importance Score:
9
BYAH
Apr 16, 2026, 7:11 AM EDT
Filing Type: F-3
Importance Score:
8
BYAH
Mar 06, 2026, 11:39 AM EST
Filing Type: 6-K
Importance Score:
8
BYAH
Mar 02, 2026, 6:57 AM EST
Filing Type: 20-F
Importance Score:
9
BYAH
Feb 13, 2026, 4:00 PM EST
Filing Type: 6-K
Importance Score:
7
BYAH
Feb 09, 2026, 8:52 PM EST
Filing Type: 6-K
Importance Score:
8
BYAH
Jan 28, 2026, 8:58 AM EST
Filing Type: 424B4
Importance Score:
9